文献速递泌尿男性生殖肿瘤

治疗抵抗性转移性前列腺癌中的复发性免疫原性新抗原及其同源T细胞受体

Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer.
PubMed 文献 · Cancer Discov · 2026-01-01

研究开发SpotNeoMet流程系统识别治疗抵抗患者中复发性呈现的新肽,发现AR H875Y突变来源的三个新肽具高免疫原性,并分离出同源TCR,在体外和体内验证其特异性杀伤前列腺癌细胞。

要点

  • SpotNeoMet可系统识别治疗抵抗突变产生的新抗原。
  • AR H875Y新肽具高免疫原性,其同源TCR特异性杀伤癌细胞。
  • 为mCRPC提供概念验证性T细胞免疫治疗策略。

核心结论

  • SpotNeoMet流程可识别治疗抵抗突变来源的新抗原,AR H875Y特异性TCR在体外和体内杀伤前列腺癌细胞。

研究设计与样本

  • 研究开发SpotNeoMet数据驱动流程,识别治疗抵抗患者中复发性呈现的新肽。
  • 使用HLA免疫肽组学发现AR H875Y来源的三个新肽,并从健康供者外周血单核细胞分离同源TCR。

主要发现

  • 识别出七个治疗抵抗突变预测产生常见HLA呈递的新肽。
  • 发现三个源自AR H875Y的新肽,验证为高免疫原性。
  • AR H875Y特异性TCR高度特异,在体外和体内杀伤呈递AR新肽的前列腺癌细胞。

临床怎么用

  • SpotNeoMet可系统识别「HLA-肽」对及其同源TCR,为治疗抵抗癌症提供免疫治疗靶点。
  • AR H875Y特异性TCR可作为mCRPC的潜在T细胞免疫治疗选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: New approaches that generate long-lasting therapeutic responses in patients with therapy-resistant metastatic cancer are urgently needed. To address this challenge, we developed Spot Neoantigens in Metastases (SpotNeoMet), a novel data-driven pipeline that systematically identifies recurrently presented neopeptides in treatment-resistant patients. We identified seven therapy resistance mutations predicted to produce neopeptides presented by common HLAs. Using HLA immunopeptidomics, we discovered three novel neopeptides derived from androgen receptor (AR) H875Y, a common metastatic castration-resistant prostate cancer (mCRPC) mutation. We validated these neoantigens as highly immunogenic and then isolated and characterized cognate T-cell receptors (TCR) from healthy donor peripheral blood mononuclear cells. We demonstrated that AR H875Y-specific TCRs are highly specific and kill prostate cancer cells presenting AR neopeptides in vitro and in vivo. Our new pipeline identifies novel immunotherapy targets and potential treatment options for patients with mCRPC. Moreover, SpotNeoMet offers a systematic route to identify "HLA-peptide" pairs and their cognate TCRs across treatment-resistant cancers. SIGNIFICANCE: As the emergence of resistance to targeted treatments in patients with metastatic cancer, there is an urgent need for innovative therapeutic approaches for this population. Our study provides a new analytic framework to identify neoantigens from treatment-resistant mutations and a proof-of-concept T cell-based immunotherapy treatment for mCRPC.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Gumpert N, Sagie S, Arnedo-Pac C, et al. Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer. Cancer Discov. 2026. PMID: 41056506. doi:10.1158/2159-8290.CD-24-1213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。